Key result
Induction therapy with cyclophosphamide and methylprednisolone led to complete recovery, including an ejection fraction of 60% at 6 months, in a 22-year-old woman with lupus myocarditis.
Case Report (n=1)
Cardiogenic shock and acute myocarditis can be rare but life-threatening initial presentations of systemic lupus erythematosus, and timely immunosuppressive therapy can lead to complete cardiac and renal recovery.
Answers are grounded in this paper and cite their sources.
May support aggressive immunosuppression in lupus myocarditis with shock; leaves open generalizability pending controlled studies.
Manifestations of cardiovascular disease from systemic lupus erythematous (SLE) ranges from subclinical findings to life-threatening conditions and may involve all cardiac tissue. In order of prevalence, findings may include pericardial disease, myocardial dysfunction, valvular heart disease, conduction system abnormalities, and atheromatous disease.1–3 There are few reports of heart failure (HF) and acute myocarditis as the initial manifestation of SLE.6–10,14,18 These are not included within the standard diagnostic criteria for SLE developed by the American College of Rheumatology.26–28 Therefore, high suspicion is necessary, since timely therapy may help achieve full recovery.15,17–19 Treatment strategies for this presentation remain empirical use of corticosteroids and immunosuppressants, based on previous case reports and cohort studies with favorable outcomes. Literature on the treatment of lupus myocarditis and nephritis is limited to few series of cases with long-term follow-up.6,18 We report the case of a young woman without known cardiac risk factors who presented with a 2-month history of worsening HF symptoms that progressed to cardiogenic shock and hypoxemic respiratory failure. She was initially treated for a suspected infectious etiology. Subsequent evaluation demonstrated lupus myocarditis and nephritis leading to her dilated cardiomyopathy and HF symptoms. She responded successfully to induction therapy with cyclophosphamide and methylprednisolone. We review the current knowledge base for diagnosis and treatment of this presentation of SLE. A 22-year-old Hispanic woman with a 6-week history of progressive dyspnea on exertion, nonproductive cough, and lower extremity edema presented to an outside facility complaining of new onset of fever, pleuritic chest pain, and fatigue. She was diagnosed with community-acquired pneumonia and started on empiric intravenous (IV) antibiotics. She was transferred to our institution after developing cardiogenic shock and hypoxemic respiratory failure that required inotropic support and mechanical ventilation. Her medical history was significant for fibromyalgia and first-degree family history of CREST syndrome. On physical examination, she was sedated, febrile, tachycardic, and hypotensive. She had jugular venous distension, bilateral decreased breath sounds with crackles at pulmonary bases, displaced apical heave lateral to mid-clavicular line with an S3 gallop, and +3 bilateral symmetric lower extremities pitting edema. Bilateral swelling of 2 through 5 proximal interphalangeal joints in her upper extremities and bilateral palpable knee effusions were also noted. A pulmonary artery catheter demonstrated elevated central venous, pulmonary artery, and wedge pressures with low cardiac output consistent with cardiogenic shock. Initial laboratory workup showed elevated serum urea nitrogen and creatinine levels at 33 mg/dL and 1.89 mg/dL, respectively; low hemoglobin and hematocrit levels of 6.9 g/dL and 21%, respectively, with a mean corpuscular volume of 71.9 fL; and normal white blood cell and platelet counts. Her liver function panel was normal. Troponin-I values peaked at 0.65 ng/mL (normal <0.04 ng/mL). An admission electrocardiogram showed sinus tachycardia with nonspecific T-wave abnormalities, and prolonged QT. Chest radiography showed bilateral pleural effusions with interstitial infiltrates and ill-defined airspace opacities in the retrocardiac region (Figure 1). Respiratory, blood, and urinary samples were sent for culture. Initial supportive management included inotropic support with dobutamine and dopamine, mechanical ventilation, IV diuretics, and broad-spectrum antibiotics with IV vancomycin and piperacillin-tazobactam. Transthoracic echocardiography (TTE) demonstrated global hypokinesis; severe systolic dysfunction with left ventricular ejection fraction 10% to 15%; mild to moderate tricuspid, pulmonary, and mitral valve regurgitation; small pericardial effusion without tamponade; and a thickened mitral valve. Results from iron panel, thyroid function tests, and viral assays (influenza A and B, Epstein-Barr virus, cytomegalovirus, and hepatitis serology) were negative. Chronic inflammatory markers were elevated, including an erythrocyte sedimentation rate (ESR) of 71 mm/h, C-reactive protein 1.81 mg/dL, and ferritin of 367 ng/mL. Despite supportive measures, her clinical status continued to deteriorate. The patient became oliguric and her creatinine peaked at 3.45 mg/dL. Urinalysis showed 50+ red blood cells, hyaline casts, and a protein/creatinine of 0.5. Renal ultrasound was negative for hydronephrosis. Urinary sediments showed muddy brown casts and dysmorphic red blood cells consistent with a mixed pattern of tubular damage and glomerulonephritis. All culture results remained negative. Rheumatologic panel (Table I) was consistent with a mixed connective tissue disorder including SLE, Sjögren syndrome, and scleroderma. The patient underwent uneventful renal biopsy, and pathology revealed diffuse proliferative glomerulonephritis (Figure 2). Chest radiography showing bilateral pleural effusion (white solid arrows) and pulmonary interstitial infiltrates consistent with acute decompensated heart failure. Renal biopsy histopathology and immunostaining. Panels A and B correspond to hematoxylin/eosin stains from renal tissue at low- and high-power, respectively, showing global mesangiocapillary proliferation with focal lobular appearance and focal mild chronic inflammation consistent with diffuse proliferative glomerulonephritis. Panels B and C are immunofluorescent stains demonstrating weak staining for IgM along the glomerular basement membranes (B) and mesangial areas with 2+ granular staining for C3 (C). Clinical and laboratory findings were consistent with lupus myocarditis and nephritis as the etiology for her dilated cardiomyopathy, HF, and subsequent cardiogenic shock. Induction treatment with pulse IV cyclophosphamide and methyleprednisolone was initiated resulting in near complete organ recovery. Prior to her discharge, her creatinine level trended down to 1.67 mg/dL. The patient was discharged home to continue a 6-month course of monthly cyclophosphamide along with a slow taper of prednisone and a regimen of β-blockers, diuretics, and digoxin. After the first month, digoxin was discontinued and furosemide was slowly tapered off. Her creatinine level and proteinuria along with ESR, C3, C4, and dsDNA levels significantly improved within 3 months of treatment and remained within normal values afterwards. She received a total of 7 doses of cyclophosphamide, achieving total recovery of her functional capacity and cardiac and renal function after 6 months of treatment. Follow-up TTE 6 months later revealed a normal ventricular size and function, with an ejection fraction 60% and no regional wall motion or valvular abnormalities. She was started on a 12- to 18-month course of maintenance therapy with mycophenolate mofetil. Follow-up laboratory workup including chemistry, urinalysis, ESR, and complement and dsDNA levels 18 months after diagnosis remained normal. Acute myocarditis and HF are uncommon but potentially fatal initial manifestations of SLE. The diagnosis is challenging due to the higher prevalence of viral myocarditis and idiopatic dilated cardiomyopathy among patients presenting with newly diagnosed HF. There are no specific signs and symptoms for lupus-associated myocarditis and HF, but overall clinical manifestations are reflective of the degree of myocardial dysfunction.1 Lupus myocarditis may present with fever, exertional dyspnea, nonproductive cough, pleuritic chest pain, and palpitations. Symptoms and signs may overlap with those of HF including fatigue, orthopnea, and peripheral edema. Additional signs may include dermatitis, joint effusions, and new cardiac murmurs/rubs in addition to the universally known clinical findings of HF including central venous distention, resting tachycardia disproportionate to body temperature, auscultable gallop, and cardiomegaly. Initial laboratory findings may be nonspecific, but included in the diagnostic criteria for SLE,26–28 such as worsening renal function, anemia, and thrombocytopenia. Serum markers of cardiac injury may be elevated, mimicking an acute myocardial infarction, stress-induced cardiomyopathy, or myocarditis.16,22,23 Chronic inflammatory markers may also be elevated. A complete rheumathologic panel must be ordered if underlying connective tissue disorder is suspected, since recent studies have demonstrated association between specific antibodies and myocarditis.7,16,29–31 In terms of diagnostics studies, the most frequent electrocardiographic findings are sinus tachycardia and nonspecific repolarization abnormalities, although conduction abnormalities, frequent premature complexes, and supraventricular and ventricular tachycardia may also be encountered.4,11,12,31 Echocardiography may reveal left ventricular (LV) dysfunction, regional or global wall motion abnormalities, and diastolic dysfunction. Valvular abnormalities and pericardial effusion may occur in conjunction with myocarditis.1,13,21 Definitive diagnosis of SLE myocarditis for the past years was thought to be achieved by endomyocardial biopsy (EMB). Several studies have shown that it may help distinguish between acute myocarditis and other causes of cardiomyopathy; nevertheless, the procedure is subject to sampling errors and thus its sensitivity and specificity for the diagnosis of lupus myocarditis remain uncertain.23–25 EMB may be associated with life-threatening complications including right ventricular perforation and tamponade with an overall rate of 6%; therefore, its use may be limited to patients who do not respond to therapy based on clinical diagnosis or in whom biopsy results could significantly alter the therapeutic approach. 24 The role of cardiac magnetic resonance imaging in providing a definitive diagnosis in this clinical setting has recently been recognized.35–37 Recent studies have demonstrated that this modality may become the primary tool for noninvasive assessment and confirmation of suspected lupus myocarditis.35,36Table II summarizes published reports and case series of lupus myocarditis with diagnostic modalities, therapy, and outcomes. In the present case, patient’s age, clinical presentation, and extensive workup ruled out coronary artery disease, including coronary anomalies, valvular heart disease, pregnancy, thyrotoxicosis, hemochromatosis, hypertension, stress, and infection as possible etiologies for her dilated cardiomyopathy. The finding of bilateral joint effusions in addition to the combination of our patient’s laboratory findings (anemia, elevated chronic inflammatory markers, urinalysis, and urinary sediment) consistent with tubular damage vs glomerulonephritis in the setting of a critically ill patient with negative infectious workup led to the suspicion of an autoimmune inflammatory disorder. Ultimately, her diagnosis was one of exclusion confirmed by positive serum immunologic markers and biopsy-confirmed lupus nephritis. Although our patient met indication criteria for EMB, which remains the gold standard for diagnosing lupus myocarditis, it was deemed unnecessary supported by the combination of biopsy-confirmed lupus nephritis and clinical response to immunosuppressive therapy. While the diagnosis of lupus myocarditis is likely, the possibility of concomitant viral myocardial myocarditis could not be excluded. An unusual feature of this patient constitutes her immunological profile, which revealed overlapping mixed connective tissue disorders including elevated titers of antinuclear antibody, dsDNA, anti-Sm, ribonucleoprotein (RNP), Ro (SS-A), La (SS-B), and SCL-70 antibodies. The significance of this broad expression of serologic antibodies in the pathogenesis of her cardiac inflammation remains to be defined. Several studies have demonstrated an association between high titers of anti-Ro,7,29,30 anti-RNP,16,31 and anti-dsDNA, with myocarditis associated or not with nephritis in patients with SLE. 5,18 The present report provides additional evidence of these associations since elevated titers of all 3 mentioned serologic markers were present in association with overt myocarditis and HF. Further studies and larger series are needed to provide statically significant data regarding these associations. Treatment strategies in patients with lupus myocarditis and HF continue to be supportive and empirical immunosuppression. Since this is an infrequent manifestation of lupus, there are no randomized controlled trials or standard guidelines available for the treatment of this condition. Most studies consist of case reports or series of cases that have demonstrated a favorable response to pulse corticosteroids alone, combined with cyclophosphamide,4–7,14,18 or other cytotoxics such as azathioprine,34 along with supportive management. Few reports have shown some benefit from the use of IV immunoglobulin (IVIG).19,32,33 In our patient, deciding the most appropriate regimen was a controversial dilemma due to the paucity of literature regarding treatment of lupus myocarditis overlapping with nephritis. She responded well to 6 months of induction therapy with pulse IV methylprednisolone and cyclophosphamide followed by maintenance therapy with mycophenolate mofetil. With this regimen, the patient achieved total functional capacity and organ recovery within 6 months of treatment. Levels of serologic and chronic inflammatory markers normalized. This specific regimen was based on the literature demonstrating that induction therapy with IV cyclophosphamide is more effective and achieved faster results than with oral cyclophosphamide or other immunossupressants in lupus nephritis38,39 in critically ill patients, in addition to a few case reports of favorable outcomes with this regimen in lupus myocarditis.4–7,14,18 Ultimately, given the scarce information regarding treatment strategies for lupus myocarditis overlapping nephritis, case reports significantly add to the growing and comprehensive knowledge base of this condition and hope for future therapeutic guidelines. In patients presenting with new-onset HF symptoms and cardiogenic shock, without a clear etiology, lupus myocarditis or lupus-like syndrome should be considered in the differential diagnosis, together with primary dilated cardiomyopathy and viral myocarditis. Lupus myocarditis should be suspected, diagnosed, and treated promptly to avoid fatal consequences. Evidence of other organ system involvement, such as glomerulonephritis, arthritis, and skin or mucosal involvement should raise the level of suspicion. The workup should include a complete rheumatologic panel, since presence or absence of certain antibodies may have a prognostic role in the future. Immunosuppressive agents are the mainstay therapy and should be started without delay to achieve survival with full organ recovery. The patient we describe had an excellent response to combined cyclophosphamide and steroid therapy, with remission and complete recovery. Further efforts to collect clinical information in these patients should probably include a multicenter registry in order to establish a consensus for diagnostic procedures, criteria, and therapeutic guidelines.
No takes yet. Share an insight, caveat, or question.
Baquero et al. (2012) conducted a case report in Systemic Lupus Erythematosus presenting with cardiogenic shock (n=1). Cyclophosphamide and methylprednisolone was evaluated on Clinical and organ recovery. Induction therapy with cyclophosphamide and methylprednisolone led to complete recovery, including an ejection fraction of 60% at 6 months, in a 22-year-old woman with lupus myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: